Stock Lower on the 52-Week Chart: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

Although there have been plenty of winners in the last year,
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) does not make the list. Over the last 52-weeks, shares have seen a drop of -56.89%. As we move deeper into the current year, investors will be keeping a close eye on the stock to see if there are any signs pointing to shares gaining some upward momentum.

Stock market reversals can occur at any given time. Sometimes, these corrections can provoke ominous forecasts from the investing community. With the market still riding high, it is important to note that market corrections can be common happenings in bull market runs. Investors may use these opportunities to buy some names at discount prices. As we move through earnings season, investors will be watching to see how companies have fared over the last quarter. Investors may want to examine sell-side analyst revisions in the weeks and days prior to the report. Investors and analysts will both be eagerly watching to see if the company can beat expectations.        

Investors following OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) may be tracking where the stock is trading in relation to its 52-week high and low. After a quick look, we see that the stock has recently touched $0.89. At this level, shares can be seen trading -75.35% away from the 52-week high mark and 63.21% off of the 52-week low. Investors often give added attention to a stock when it is closing in on either level.

Looking at past performance for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), we note that the stock has moved 19.61% over the last five sessions. Over the previous month, shares have performed 14.25%. If we look back to the start of the calendar year, we see that the stock has performed 19.40%. For the last quarter, the stock has changed -40.51%. Investing in the stock market often includes calculating risk and weighing it against possible reward. Taking on too much risk may put the investor in a tough spot. On the other end, taking on too little risk may not give enough opportunity to achieve previously set goals. Discovering that perfect mix may come with some experience along with some extended time in the market.

Let’s check on some analyst views for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Tallying the individual scores, we note that the consensus recommendation is presently 3.00. This number follows a one to five scale where a one would indicate a buy and a five would indicate a sell. Stock market investing can sometimes become very emotional. Leaving emotions out of the major investing decisions might be tough, but it may end up helping the portfolio in the long run. Nobody wants to see a thoroughly researched stock pick go haywire. Holding onto the hope that a certain stock has to bounce back may lead to future struggles.

After a recent check on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), we can see that the current consensus target price is $1.50. Analysts often work hard to analyze stocks that they cover. Because each covering analyst may come to a different conclusion about where shares are headed, investors often look to the consensus number in order to get an overall sense of the outlook.

Individual investors have the tendency to migrate towards certain stock strategies that have been successful in the past. While following previous strategies may be profitable, investors have to be ready for sudden market changes. Most investors will rejoice when stocks in the portfolio catch a hot streak. On the opposite side, investors may become highly dejected when they experience a prolonged losing streak. Sometimes, previously successful strategies run their course and they no longer work. Investors may benefit greatly from being able to make adjustments when the market takes a turn for the worse. 

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.